Form 4: Dyne Therapeutics CMO Sells Shares for Tax Obligations

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, sold 904 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc. (DYN), reported a sale of common stock.
• The transaction involved the disposition of 904 shares of common stock at a price of $14.9 per share.
• The sale occurred on March 5, 2026, and was executed to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
• The RSUs were granted to Mr. Kerr on December 4, 2024.
• This sale was automatic and non-discretionary, conducted under a Rule 10b5-1(c) plan, and does not represent a discretionary trade by the Reporting Person.
• Following this transaction, Mr. Kerr beneficially owns 171,606 shares of common stock, which includes 153,625 unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction for tax purposes related to RSU vesting and does not reflect a change in the insider's view of the company's prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine occurrence across all industries, particularly for publicly traded companies that use equity compensation.

Comparison to Industry Standards

• StockSavvy.ai notes that non-discretionary sales for tax withholding are standard practice across industries for executives receiving equity compensation. This type of transaction is widely observed among peers in the biotechnology and pharmaceutical sectors, such as Biogen Inc. (BIIB) or Vertex Pharmaceuticals Inc. (VRTX), where equity awards are a significant component of executive compensation packages.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the company's operational or financial outlook.

Key Dates

Recommendation

The sale of shares by Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, was a non-discretionary transaction to cover tax withholding obligations related to the vesting of restricted stock units. This is a routine event for executives receiving equity compensation and does not reflect a change in management's confidence or the company's fundamentals, thus warranting a 'hold' recommendation.

Keywords

Dyne Therapeutics, DYN, Insider Transaction, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Douglas Kerr, 10b5-1 Plan